赫赛汀与多西他赛联合应用治疗HER-2阳性转移性乳腺癌疗效分析

目的分析赫赛汀与多西他赛联合应用治疗人类表皮生长因子受体-2(HER-2)过表达的转移性乳腺癌的临床疗效。方法随机选取2011年1月至2013年12月期间收治的39例HER-2阳性的转移性乳腺癌患者,分成观察组和对照组。观察组给予赫赛汀联合多西他赛方案化疗,对照组给予赫赛汀联合长春瑞滨方案化疗。观察对比两组临床疗效及不良反应。结果观察组总有效为21例(78.8%),患者临床受益为23例(85.2%);对照组总有效为5例(41.7%),患者临床受益为7例(58.3%)。观察组总有效率显著优于对照组,差异具有统计学意义(P0.05);两组临床受益率对比,差异无统计学意义(P0.05)。两组患者临床不良反应均不明显,主要不良反应表现为发热、皮疹、骨髓抑制以及胃肠道不适。结论赫赛汀与多西他赛联合应用治疗HER-2阳性转移性乳腺癌具有良好的临床疗效及安全性,值得临床推广应用。

Efficacy on herceptin and docetaxel combination treatment of HER-2 positive metastatic breast cancer

Objective To analyse the clinical effect of herceptin in combination with docetaxel in treating patients with HER-2 positive metastatic breast cancer. Methods 39 cases of HER-2-positive metastatic breast cancer form January 2011 to December 2013 were randomly divided into observation group and control group. The observation group was treated with herceptin combination with docetaxel. The control group was treated with herceptin combination with vinorelbine chemotherapy. The clinical efficacy and adverse reactions were observed and compared be-tween two groups. Results The total effective rate was 78. 8%,patients with clinical benefit rate was 85. 2% in the observation group;which was 41. 7% and 58. 3% in the control group. The total efficiency in observation group was significantly better than in the control group（ P 〈0. 05）. There was no significant differences in clinical benefit rate（ P 〉0. 05）. Patients were not clinically significant adverse reactions,the main adverse reactions manifested as fever,rash,bone marrow suppression and gastrointestinal discomfort. Conclusion Therapy of herceptin in combination with docetaxel in treating patients with HER-2 positive metastatic breast cancer have good clinical efficacy and safety. It is worthy of wider promo-tion.